Advances in Understanding and Managing Autoimmune Hepatitis: A Narrative Review

Yadav, Vikas; Irfan, Rabbia; Safdar, Shamayel; Sunkara, Vyshnavidevi; Ekhator, Chukwuyem; Pendyala, Praful R; Devi, Monika; Shahzed, S M Iram; Das, Archana; Affaf, Maryam; Bellegarde, Sophia B; Shrestha, Riya; Naseem, Muhammad Arsal; Al Khalifa, Ahmed

doi:10.7759/cureus.43973

Cited by 1 publication

(1 citation statement)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Основная цель назначения преднизолона -индукция ремиссии, тогда как азатиоприна -ее поддержание [1,5,6]. Отсутствие достаточного эффекта или плохая переносимость преднизолона и азатиоприна дают основания для попытки назначения других иммуносупрессоров, таких как циклофосфамид, микофенолата мофетил, циклоспорин, такролимус [9,10].…”

unclassified

Immunological Remission as a Basis for Dose Reduction of Immunosuppressors in Autoimmune Hepatitis: Results of Monocenter Surveillance Study

Bueverov,

Koblov,

Bogomolov

2024

Rossijskij žurnal gastroènterologii, gepatologii, koloproktolog

View full text Add to dashboard Cite

Aim of the study: evaluate the role of normalization of humoral immunity to address dose reduction or discontinuation of immunosuppressors in patients with autoimmune hepatitis (AIH).Patients and methods. The data of 47 patients with AIH who received immunosuppressive therapy from April 2001 to August 2023 were analyzed: 10 men (21 %), 37 women (79 %); the average age was 37 (17–66) years. The follow-up period was 10–180 months. Type 1 AIH was diagnosed in 37 patients, type 2 AIH — in 7 patients, seronegative AIH — in 3 patients. The diagnosis was established according to the IAIHG point system. To confirm the diagnosis, a liver biopsy was performed in 17 patients, a histological picture of AIH was detected in all of them. The most used combination was prednisolone and azathioprine — in 25 patients (53.2 %), as well as methylprednisolone and azathioprine — in 8 patients (17 %).Results. In some patients, when the immunosuppressive therapy decreased below the recommended dose, a relapse of the disease developed (Group 1), and in others, remission persisted (Group 2). The concentration of гамма-globulins in patients of Group 1 was 22.5 mg%, in Group 2 — 17.95 mg% (p = 0.00055). IgG level after achieving remission in Group 1 was 1709.7 mg/dL, in Group 2 — 1381.7 mg/dL (p = 0.000001). The terms of ALT normalization in Group 1 were 2.14 months, in Group 2 — 1.47 months (p = 0.037); AST normalization in Group 1 made 2.22 months, in Group 2 — 1.48 months (p = 0.026).Conclusions. Normalization of humoral immunity, as well as rapid normalization of ALT and AST can be considered as markers of maintaining AIH remission when immunosuppressor doses are reduced below standard doses, and in individual patients — the possibility of immunosuppressive therapy withdrawal. This will reduce the risk of adverse events and increase adherence to the therapy. We propose introducing the term “immunological remission” into the clinical lexicon, which, along with biochemical and histological remission, acts as a predictor of persistent remission of AIH.

show abstract

unclassified